好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Outcomes of Status Epilepticus in Elderly: a systematic review.
Epilepsy/Clinical Neurophysiology (EEG)
P2 - Poster Session 2 (5:30 PM-6:30 PM)
6-018

To systematically review and evaluate the outcome of Status Epilepticus (SE) including mortality and functional outcomes in elderly population.

Status epilepticus is associated with high mortality and morbidity. SE is frequently seen in elderly with limited data available on morbidity and functional outcomes. 

A systematic search was conducted of Cochrane, PubMed, CINAHL, and EMBASE electronic databases on April 19th, 2018. Inclusion criteria were studies with clearly defined elderly population (≥ 60 year-old), number of patients ≥3, status epilepticus, and report of outcomes. Various outcomes including mortality, short-term, and long-term functional outcomes were collected.

2669 titles and abstracts were screened from the initial search after removal of duplicates. 431 full text articles were reviewed in detail, and 88 studies were included in the final review. Most studies were descriptive and did not report statistical significance for the outcomes. Mortality was reported in 67 studies among which 19 studies were statistically significant and 5 studies were not significant. Mortality was reported descriptively in the rest 37 studies.  “Good” and “poor” outcomes were reported in 28 studies out of which 7 studies showed significantly poor outcome and 1 study showed significantly good outcome in elderly compared to the younger population. Neurologic sequelae after SE were reported in 13 studies among which 2 studies were significant compared to non-elderly population. Functional outcomes including modified Rankin Scale (mRS) (N=8), Status Epilepticus Severity Score (N=7) and Glasgow Outcome Scale (N=2) were reported descriptively but did show worsening compared to either preadmission or younger population enrolled in studies.

This review provided preliminary evidence that SE in elderly results in increased mortality, unfavorable outcomes, and worsened functional outcomes. However, most studies were descriptive of their findings. Future studies with more detailed outcome measures and more use of statistical methods should be considered in this population.

Authors/Disclosures
Mahsa Sadeghi, MD
PRESENTER
Dr. Sadeghi has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Mihir Kakara, MD Dr. Kakara has nothing to disclose.
Morad Nasseri, MD (BHC) No disclosure on file
Advait Mahulikar, MD (Mercy Neurology) No disclosure on file
Rohit A. Marawar, MD, FAAN (Wayne State University - Detroit Medical Center) Dr. Marawar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Marawar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SK Pharma. Dr. Marawar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon. Dr. Marawar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurelis.